Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tedeschi, Alessandra, Frustaci, Anna Maria, Mauro, Francesca Romana, Chiarenza, Annalisa, Coscia, Marta, Ciolli, Stefania, Reda, Gianluigi, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Baratè, Claudia, Sportoletti, Paolo, Greco, Antonino, Borella, Chiara, Rossi, Valentina, Deodato, Marina, Biagi, Annalisa, Zamprogna, Giulia, Pelle, Angelo Curto, Lapietra, Gianfranco, Vitale, Candida, Morelli, Francesca, Cassin, Ramona, Fresa, Alberto, Cavalloni, Chiara, Postorino, Massimiliano, Ielo, Claudia, Cairoli, Roberto, Di Raimondo, Francesco, Montillo, Marco, Del Poeta, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714729/
https://www.ncbi.nlm.nih.gov/pubmed/34525181
http://dx.doi.org/10.1182/bloodadvances.2021004824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714729/
https://www.ncbi.nlm.nih.gov/pubmed/34525181
http://dx.doi.org/10.1182/bloodadvances.2021004824

Ejemplares similares